Journal of Thoracic Oncology
| 短名 | J. Thorac. Oncol. |
| Journal Impact | 21.06 |
| 国际分区 | RESPIRATORY SYSTEM(Q1) |
| 期刊索引 | SCI Q1中科院 1 区 |
| ISSN | 1556-0864, 1556-1380 |
| h-index | 178 |
| 国内分区 | 医学(1区)医学肿瘤学(1区)医学呼吸系统(1区) |
| Top期刊 | 是 |
JOURNAL OF THORACIC ONCOLOGY (JTO) 是国际肺癌研究协会的官方期刊，是有关预防、检测、诊断和治疗所有胸部恶性肿瘤的主题的主要教育和信息出版物。 JTO 强调多学科方法，包括原创研究评论和意见。观众包括流行病学家、内科肿瘤学家、放射肿瘤学家、胸外科医生、肺科医师、放射科医师、病理学家、核医学医师以及对胸部肿瘤学特别感兴趣的研究科学家。
期刊主页投稿网址| 涉及主题 | 医学内科学生物肿瘤科病理遗传学肺癌癌症外科化学生物化学放射科哲学语言学癌症研究肺免疫学 |
| 出版信息 | 出版商: Elsevier Inc.，出版周期: Monthly，期刊类型: journal |
| 基本数据 | 创刊年份: 2006，原创研究文献占比: 87.91%，自引率:4.30%， Gold OA占比: 83.71% |
| 平均审稿周期 | 网友分享经验：一般,3-6周 |
| 平均录用比例 | 网友分享经验：较易 |
期刊引文格式
这些示例是对学术期刊文章的引用，以及它们应该如何出现在您的参考文献中。
并非所有期刊都按卷和期组织其已发表的文章，因此这些字段是可选的。有些电子期刊不提供页面范围，而是列出文章标识符。在这种情况下，使用文章标识符而不是页面范围是安全的。
只有1位作者的期刊
有2位作者的期刊
有3位作者的期刊
有5位以上作者的期刊
书籍引用格式
以下是创作和编辑的书籍的参考文献的示例。
学位论文引用格式
网页引用格式
这些示例是对网页的引用，以及它们应该如何出现在您的参考文献中。
专利引用格式
最新文章
Board of Directors
2024-9-1
In This Issue
2024-9-1
Table of Contents
2024-9-1
Response to: “The Value of Incidental Imaging for Early Stage Lung Cancer in High-Risk Nonscreening Cohort: Some Additional Considerations?”
2024-9-1
Lung Cancer in Finland
2024-9-1
A Response to the Letter to the Editor: Comment on “Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS(G12C)-Mutated NSCLC Treated With Sotorasib”
2024-9-1
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes from the Phase 3 POSEIDON Trial
2024-9-1
Editorial Board
2024-9-1
High-dose Furmonertinib in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases: A prospective real-world study
2024-9-1
Beyond Low-Dose Computed Tomography: Emerging Diagnostic Tools for Early Lung Cancer Detection
2024-9-1
Future Radiation Oncology: The Role of Personalization and Standardization in Stereotactic Body Radiotherapy
2024-9-1
A Response to the Letter to the Editor: The Role of Personalization and Standardization in Stereotactic Body Radiation Therapy
2024-9-1
A Response to the Letter to the Editor: Safety Implications of Switching Pembrolizumab Dosage From 200 mg Every 3 Weeks to 400 mg Every 6 Weeks in Patients With Advanced NSCLC
2024-9-1
Suggestions for Improving the Comprehensive Characterization of Lung Pleomorphic Carcinoma
2024-9-1
Meeting Announcements
2024-9-1
Tobacco News Update—From the IASLC Tobacco Control Committee
2024-9-1
Executive Summary of the American Radium Society® (ARS) Appropriate Use Criteria (AUC) for Non-Small Cell Lung Cancer in a Central/Ultra-Central Location: Systematic Review and Guidelines
2024-9-1
Consolidation ALK Tyrosine Kinase Inhibitors versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK+ Non-Small Cell Lung Cancer
2024-9-1
The Value of Incidental Imaging for Early-Stage Lung Cancer in a High-Risk Non-Screening Cohort: Some Additional Considerations?
2024-9-1
Suggestions for the predictive factors related to irAES and research methods during dose switching of pembrolizumab treatment in patients with advanced NSCLC
2024-9-1
Suggestions for Improving the Comprehensive Characterization of Lung Pleomorphic Carcinoma
2024-9-1
Comment on “Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS(G12C)-Mutated NSCLC Treated With Sotorasib”
2024-9-1
Erratum to “Treatment response biomarkers: working towards personalised radiotherapy for lung cancer. [Journal of Thoracic Oncology Vol. 19 No. 8: 1164–1185]”
2024-9-1
A Response Letter by Cameron et al
2024-8-1
Lung Cancer in Estonia
2024-8-1
Tobacco News Update—From the IASLC Tobacco Control Committee
2024-8-1
Which Factor Determines the Survival Outcome After Surgery in Patients With Thymoma Distant Recurrence?
2024-8-1
“Tumor-free survival” Does Not Outweigh the Adverse Effects of Anti-EGFR Therapy and Chemotherapy in Patients With NSCLC
2024-8-1
In This Issue
2024-8-1
Erratum
2024-8-1
Erratum
2024-8-1
Letter Regarding “Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRASG12C-Mutated NSCLC Treated With Sotorasib”
2024-8-1
Efficacy and safety of KRAS G12C inhibitor IBI351 monotherapy in patients with advanced non-small cell lung cancer: results from a phase 2 pivotal study
2024-8-1
Shades of Gray: Do Never Smokers Benefit From Lung Cancer Screening Programs?
2024-8-1
Editorial Comment: Validation Study for the N Descriptor of the Newly Proposed 9th Edition of the TNM Staging System Proposed by the International Association for the Study of Lung Cancer
2024-8-1
Erratum
2024-8-1
Response to Letter to the Editor
2024-8-1
Encouraging Fussy Eaters in EGFR-Mutated Lung Cancer
2024-8-1
Screening Low-Risk Individuals for Lung Cancer: The Need May Be Present, but the Evidence of Benefit Is Not
2024-8-1
Accurate Prognostic Factor for Carbon-Ion Radiotherapy in Operable Stage I NSCLC
2024-8-1
Letter Regarding “Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRASG12C-Mutated NSCLC Treated With Sotorasib”
2024-8-1
Meeting Announcements
2024-8-1
Lung-MAP Next Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400)
2024-8-1
A Response to the Letter to the Editor: “Prognostic Factors for Survival After Thymoma Distant Recurrence Resection”
2024-8-1
From the IASLC Early Detection and Screening Committee Terminology Issues in Screening and Early Detection of Lung Cancer – IASLC Early Detection and Screening Committee Expert Group Recommendations
2024-8-1
The Devil Is in the Details: A Hidden Obstacle to Implementing the Proposed Revision of the N Descriptors in the Ninth Edition of the TNM Classification for Lung Cancer
2024-8-1
Author’s Reply
2024-8-1
The Number of Chemoimmunotherapy Cycles and Clinical Outcomes in Resectable NSCLC
2024-8-1
“Tumor-Free Survival” Outweighs the Side Effects of Combined Anti-EGF Therapy and Chemotherapy in Patients With NSCLC
2024-8-1
Board of Directors
2024-8-1
帮你贴心管理全部的文献
研飞ivySCI，高效的论文管理
投稿经验分享
分享我的经验，帮你走得更远